Vor Biopharma (NASDAQ:VOR) Stock Jumps 5.3% - Here's What Happened

Key Points

• Vor Biopharma shares rose 5.3% to about $19.31 in mid-day trading, although trading volume was roughly 91% below the average session volume.
• Analyst sentiment is broadly positive: the stock has a “Moderate Buy” consensus rating and a $41.71 average price target, despite Wedbush maintaining a neutral rating.
• The company reported a quarterly loss of $0.80 per share, missing estimates by $0.11, while hedge funds and other institutional investors own approximately 97.29% of the stock.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report)'s stock price rose 5.3% during mid-day trading on Wednesday. The company traded as high as $19.30 and last traded at $19.3050. Approximately 100,789 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 1,068,548 shares. The stock had previously closed at $18.33.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Wedbush increased their price objective on Vor Biopharma from $18.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, August 12th. Weiss Ratings raised shares of Vor Biopharma from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, September 14th. Finally, Wall Street Zen upgraded shares of Vor Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $41.71.

Vor Biopharma Stock Performance

The stock has a 50 day simple moving average of $22.12 and a two-hundred day simple moving average of $17.89.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). Equities analysts forecast that Vor Biopharma Inc. will post -2.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

A number of institutional investors have recently bought and sold shares of the company. Fcpm Iii Services B.V. boosted its holdings in Vor Biopharma by 852.8% in the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company's stock valued at $47,315,000 after purchasing an additional 3,237,714 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in shares of Vor Biopharma during the 4th quarter worth approximately $33,275,000. NEXTBio Capital Management LP acquired a new stake in shares of Vor Biopharma during the 4th quarter worth approximately $13,080,000. Braidwell LP raised its position in shares of Vor Biopharma by 22.8% during the 2nd quarter. Braidwell LP now owns 573,104 shares of the company's stock valued at $10,551,000 after buying an additional 106,330 shares during the period. Finally, Findell Capital Management LLC purchased a new stake in shares of Vor Biopharma during the 4th quarter valued at approximately $3,021,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing treatments for patients with hematologic malignancies, including acute myeloid leukemia (AML). The company combines engineered hematopoietic stem cell therapies with targeted cancer medicines in an effort to improve the selectivity and effectiveness of treatment.

Vor's lead program, trem-cel (formerly known as VOR33), is an investigational gene-edited hematopoietic stem cell therapy designed to eliminate the CD33 protein from blood-forming stem cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.